Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Agent Selectively Targets Malignant B Cells

May 4, 2011 11:46 am | News | Comments

A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia (CLL). A study shows that PCI-32765 selectively kills the malignant B lymphocytes that cause CLL.

TOPICS:

Molecule Offers Hope in Spinal Cord Injuries

May 4, 2011 11:42 am | News | Comments

Researchers have developed a treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing, and minimize pain. The treatment works by reducing production of a protein called RhoA.

TOPICS:

HIV Drug Could Prevent Cervical Cancer

May 4, 2011 11:21 am | News | Comments

Researchers have discovered how the antiviral drug lopinavir attacks HPV by switching on a natural viral defence system in infected cells. The study identifies lopinavir as a potential therapeutic for HPV-related cervical cancer.

TOPICS:
Advertisement

Nanovaults Used to Prod Immune System

May 4, 2011 11:15 am | News | Comments

Scientists have discovered a way to "wake up" the immune system to fight cancer by delivering an immune system–stimulating protein in a nanoscale container called a vault directly into lung cancer tumors.

TOPICS:

University of Leipzig Purchases CellHesion 200

May 4, 2011 11:11 am | News | Comments

JPK Instruments, a manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports that the University of Leipzig has chosen the CellHesion 200 system for their Institute of Experimental Physics I.

TOPICS:

Almac Expands Biocatalysis Business

May 4, 2011 11:04 am | News | Comments

Almac’s biocatalysis business has expanded from its 2009 launch to the supply hundreds of kilograms of chiral intermediates for drug substance manufacture and enzyme supply to specialty chemical companies.

TOPICS:

Liquid Handling System

May 4, 2011 10:35 am | Product Releases | Comments

Agilent Automation Solutions has released an application note that demonstrates how its Bravo liquid handling system provides an efficient platform for automation of a SISCAPA Magnetic Bead Workflow for protein biomarker quantification by mass spectrometry.

TOPICS:

ChIP Assay Kit

May 4, 2011 10:31 am | Drug Discovery & Development, Drug Discovery & Development | Product Releases | Comments

Porvair Filtration Group has announced the launch of the first product, a ChIP kit containing 24 assays, based upon its novel Chromatrap Pro-A Chromatin ImmunoPrecipitation technology.

TOPICS:
Advertisement

Daiichi Sankyo Launching Alzheimer's Pill

May 4, 2011 10:26 am | News | Comments

Daiichi Sankyo Company, Limited announced that it will launch Memary 5mg, 10mg and 20mg Tablets given once daily for the treatment of moderate to severe Alzheimer's Disease.

TOPICS:

Molecular Partners Completes Two Trials

May 4, 2011 9:44 am | News | Comments

Molecular Partners AG announced that it has completed two phase 1/2a clinical trials with MP0112, its lead molecule targeting VEGF-alpha. The DARPin molecule was shown to be safe and well tolerated in two separate Phase 1/2a trials.

TOPICS:

Beijing Second Pharma Earns ANDA Approval

May 4, 2011 9:29 am | News | Comments

Beijing Second Pharmaceutical Co., Ltd. has gained U.S. Food and Drug Administration approval of ANDA 090752 for amlodipine besylate, becoming the first Chinese-owned pharma firm to be able to launch an FDA-approved oral solid dose product in the U.S.

TOPICS:

No SMC Concerns in Late-Stage Trials

May 4, 2011 9:21 am | News | Comments

Nymox Pharmaceutical Corporation announced that a recent Safety Monitoring Committee meeting found no significant safety concerns to date for its ongoing Phase 3 trials for NX-1207, an investigational drug for benign prostatic hyperplasia.

TOPICS:

Hatchtech Pty Ltd Commences 2b Clinical Trial

May 4, 2011 9:08 am | News | Comments

Hatchtech Pty Ltd has enrolled the first subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo.

TOPICS:

Perrigo's 3Q Profit Soars 43%

May 4, 2011 9:08 am | News | Comments

Perrigo Co., which makes store-brand, over-the-counter drugs and infant formulas, said its fiscal third-quarter earnings jumped 43 percent, helped by new product sales and gains in some existing categories.

TOPICS:

FDA Approves OTC Minoxidil Foam

May 4, 2011 9:06 am | News | Comments

Perrigo Company received final approval from the FDA for its abbreviated new drug application for over-the-counter (OTC) Minoxidil Foam.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading